Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms EMBRACE study
- 15 Nov 2017 Planned initiation date changed from 30 Sep 2017 to 30 Nov 2017.
- 15 Nov 2017 Status changed from not yet recruiting to recruiting.
- 13 Jun 2017 New trial record